Navigation Links
Potential Target for Leukemia Treatment

Cincinnati Children’s Hospital Medical Center today announced the publication of pioneering research identifying the crucial role // and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. The findings, along with other studies, suggest that RhoH GTPase may provide a target for therapeutic intervention in some types of leukemia.

The paper describes detailed genetic and biochemical studies undertaken by researchers in the Division of Experimental Hematology and the Division of Immunobiology. The investigators succeeded in identifying a crucial role for RhoH GTPase in the development of thymocytes and activation of T-lymphocytes, both key processes in immune cell development. In addition, the researchers uncovered a novel mechanism for regulating RhoH activity, which may have broad implications in improving researchers’ understanding of the mechanism of action of the Rho GTPase protein family and provide a potential target for leukemia drug development.

“We continue to make important progress in deciphering the molecular processes involved in the development and maintenance of the immune and blood system and how disruption of key proteins may contribute to leukemia,” said David A Williams, M.D., Director of Experimental Hematology, Cincinnati Children’s. “Through a collaboration with Ohio State University Comprehensive Cancer Center, we are now focused on translating these findings into developing new ways to target the protein as a novel approach to treating hematological malignancy.”

The development of mature white blood cells, including lymphocytes, is a highly complex process involving cell growth as well as specific genetic and biochemical steps. Disruption of this process is associated with diseases such as leukemia.

RhoH GTPase is specific to blood-forming cells. Experiments have shown that its alteration affects several key steps in the g
'"/>




Page: 1 2

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
Post Your Comments:
(Date:12/2/2008)...Newswire/ -- diaDexus, Inc. today,announced that ...mat of the,PLAC Test for Lp-PLA2. This automated ... a wide range of clinical chemistry analyzers, was...tration (FDA) in December 2007. diaDexus also,ann...st to Europe. , The PLAC Test is the only b...
(Date:12/2/2008)...t a symposium today hosted by Johns,Hopkins Univ...archers presented,the latest research in brain pl...cience into technology to improve lives. Henry Mah...vidence that cognitive intervention developed by,...brain,s ability to,reorganize itself throughout l...
(Date:12/2/2008)...ewswire/ -- Are you unhappy with your smile but ar...ailable? , , The Pennsylvania Dental Associ...ptions exist to improve your smile. Your dentist c... determine a suitable option to help restore your ...tal options. , , , , Tooth whi...
(Date:12/2/2008)...ed for 3.5 percent of high school athletes, injuri... to examine rare injuries and conditions of U.S. h...uries, dental injuries, neck and cervical injuries...t in high morbidity, costly surgeries and treatmen... associated with the highest rate of rare injuries...
Breaking Medicine News(10 mins):Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:Cosmetic Dentistry: A Beautiful Smile Is Not Far Away 2
...riggered by viral cold are common in preschoolers....since the frequency disappears by school age. //Th...r oral steroids at the first sign of an attack. Bu...ive is controversial. The research shows a course...
...be a major improvement for HIV patients in less-de...sess a patient's response to HIV medication.// HIV... This treatment is now becoming available in Afric...etermine the CD4 cell count are needed. A low CD4 ...
...to help acne patients. A new study highlights the ...is is important because this skin disease can lead...b and sometimes even suicide. Doctors from London ...ate facial acne. Thirty-one of the patients receiv...
...is year’s meeting of the American Society of Thera...ment //of external beam radiation may be what it t...ers that have spread to the bone. More than 160 ho... States and Canada were involved in a study of abo...
Other Medicine News:
(Date:12/2/2008)... Horizon Therapeutics, Inc., a,pr...unced that two pivotal,Phase 3 trials evaluating ...1,met all primary endpoints. HZT-501, a novel, p...ing ibuprofen and famotidine, demonstrated a,stat...f non-steroidal,anti-inflammatory drug (NSAID)-in...
(Date:12/1/2008)...ICAGO, Dec. 2 A study h... a new technique for imaging the breast, is not af...nal status, two factors that limit the effectivene...ncer. Results will be presented today at the annua...rica (RSNA). , , "The ability of PEM to de...
(Date:12/1/2008)...RNewswire/ -- S*BIO Pte Ltd today announced the in...a potent and orally-active JAK2 inhibitor, in lead... chronic idiopathic myelofibrosis (CIMF). , ,...nd tolerability of SB1518 in patients with CIMF an...se 1 part of the study will assess the safety prof...
(Date:12/1/2008)... the Prox1 gene is a two-way switch that, if turne...programmed so that they lose their identity and be...MEMPHIS, Tenn., Dec. 1 ...al have discovered that a certain differentiated c...t requires the constant expression of a gene calle...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3After Effects 3A Giving Back Is Good for You 19422 1After Effects 3A Giving Back Is Good for You 19422 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 1Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 5Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 1Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 2AUA 2008 3A Global warming may lead to increase in kidney stones disease 19414 1
...IDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCel.... Beer, President and,Chief Executive Officer of V...ivities and product pipeline at the C.E. Unterberg...on Tuesday, July,10, 2007 at 3:00 p.m. at the Mand...webcast of the presentation will be available on,t...
...ESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMT...ion (Nasdaq:GNBT), the,leader in drug delivery for...e mouth, announced today that it will be making th...g of the European,Society of Pediatric Endocrinolo...rget="_blank" href=,"http://www.espe2007.org/">www...
Other Medicine Technology:Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 3
... integrated technology and service--mobile,outpati...heartbeat, ECG monitoring, analysis and response, ...y focused on helping physicians diagnose and treat...in diagnosing and treating arrhythmia. Delays can ...
...rmance temperature controlled shaker which accommo...eed and incubation time are fully programmable via...ed on the LCD in real time. Microprocessor-control... provide uniform incubation with less than 0.6 C v...
The iEMS Incubator/Shaker HT is designed for extended temperatures. Thus, the iEMS Incubator/Shaker HT is ideal for applications such as DNA hybridization and primer extension assays. iEMS Incubator/
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -
Medicine Products: